Study of Clinical Features, Treatments, and Outcomes in Adults with Inflammation-Associated Non-Rapidly-Progressive Coronary Artery Disease INR-CAD

What this Trial Is About

Researchers are studying a special type of coronary artery disease called inflammation-associated non-rapidly-progressive coronary artery disease INR-CAD. This condition differs from typical atherosclerotic coronary artery disease by affecting mainly women, starting earlier in life, lacking traditional risk factors, showing signs of chronic inflammation, and responding differently to treatments. The study aims to understand the clinical features, current treatments, and outcomes in patients with INR-CAD through an observational cohort design. Patients diagnosed with INR-CAD are identified based on specific clinical criteria including coronary artery lesions and evidence of chronic inflammation. They receive follow-up care over 24 months according to a protocol designed for INR-CAD. Treatments under evaluation include healthy lifestyle changes, secondary prevention medications for atherosclerosis, immunosuppressive therapy, coronary revascularization procedures like PCI or CABG, and supportive therapies to manage side effects. Participants will undergo various assessments during the 24-month follow-up, including monitoring for major adverse cardiovascular events MACE such as heart attacks and hospitalizations. Researchers will also measure exercise capacity, detailed angiographic features of coronary lesions, and inflammatory markers like ESR, hs-CRP, IL-6, and TNF-alpha. Safety outcomes like major bleeding and severe infections will be tracked. The study will compare outcomes between patients with different diagnoses and treatments to better understand INR-CADs progression and management.

Clinical Features, Current Treatment and Clinical Outcomes in Patients With INR-CAD: a Cohort Study